<DOC>
	<DOCNO>NCT01281293</DOCNO>
	<brief_summary>Vagus Nerve Stimulation ( VNS ) Therapy approve marked treatment epilepsy since 1994 . This post-market study design follow clinical course outcomes patient refractory seizure treat adjunctive VNS Therapy . Seizure frequency , seizure severity , side effect burden , depressive symptom , global impression , health care utilization evaluate . The result study provide data guide physician patient use VNS Therapy patient refractory seizure fail initial trial anti-epileptic drug ( AED ) therapy . The data collect purpose confirmatory assessment .</brief_summary>
	<brief_title>Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively Patients Stimulated</brief_title>
	<detailed_description>Minimum age eligible E-103 study least 7 year outside US , consistent `` Non-US '' label 12 year sit US .</detailed_description>
	<criteria>Patients enrol study must meet follow criterion Visit 1 : ( Baseline ) Screening Incl/Excl omit : 1 . Patients must agree treated VNS Therapy . The decision treat VNS Therapy must make independent prior participation study . 2 . Patients participate Sites locate US must follow `` NonUS '' label least 7 year old whose epileptic disorder dominate partial seizure ( without secondary generalization ) generalize seizure refractory antiepileptic medication ; patient participate Sites locate United States must 12 year older partial onset seizure must follow indication use statement ( VNS Therapy ) country origin . 3 . Patient and/or caregiver must able give accurate seizure count , health outcome information , complete study instrument minimal assistance . 4 . Patient legal guardian understands study procedure voluntarily sign inform consent United States Health Insurance Portability Accountability Act ( HIPAA ) authorization accordance institutional policy . In event patient age 18 patient also require sign assent affirm agreement participate research accord local IRB requirement . Similar authorization require per EC requirement , equivalent authority . Additional Continuation Criteria evaluate Visit 2 ( Baseline ) : 5 . Patient must take least 1 antiepileptic drug treatment stable say medication least 8 week ( 56 day ) prior baseline . ( Rescue medication may allow caseby case basis Cyberonics approval . ) 6 . Patient must minimum frequency 3 seizure ( exclude absence seizure , simple partial seizure myoclonic jerk ) per month ( average 2 month ) prior baseline ; maximum frequency 20 seizure per day . 7 . Patient must 4 week seizure ( 2 month ) prior baseline . Patients follow eligible enrollment : 1 . Patient currently use , expect use study , shortwave diathermy , microwave diathermy , therapeutic ultrasound diathermy . 2 . Patient expect require full body magnetic resonance image clinical study . 3 . Patient progressive neurological condition ( e.g . brain tumor etc. ) . 4 . In investigator 's opinion , inability patient , legal guardian reluctance child comply frequency clinic visit treatment phase . 5 . In investigator 's opinion , patient history noncompliance seizure diary completion . 6 . Patient currently use investigational device pharmacologic medication approve either EU US regulatory authority . 7 . Patient previous VNS Therapy implant . 8 . In investigator 's opinion , patient suicidal .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>V-COMPAS ; Vagus Nerve Stimulation Clinical Outcomes ;</keyword>
</DOC>